What's new in HCV genotype 2 treatment

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 135-140

  Mangia, Alessandra ^a   Mottola, Leonardo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Boceprevir; Direct acting antivirals; Hepatitis C; IL28B polymorphism; Interferon; Ribavirin; Short duration treatment; Telaprevir

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; DRUG ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONOTHERAPY; NONHUMAN; PREVALENCE; REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84855242247     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02710.x     Document Type: Review

References (42)

1. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(Suppl. 2): 30-60.
2. Mangia A, Cascavilla I, Lezzi G, et al. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 1997; 26: 1173-8.
3. Mariano A, Scalia TG, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009; 41: 689-99.
4. World Health organization (WHO). Hepatitis C virus. Available at: Accessed 1 September 2011.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-47.
8. Powis J, Peltekian KM, Lee SS, et al. Canadian Pegasys Study Group. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008; 15: 52-7.
9. Bochud PY, Cai T, Overbeck K, et al. On behalf of the Swiss Hepatitis C Cohort Study. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.
10. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
11. Jacobson IM, Brown RS Jr, Freilich B, et al. WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81.
12. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011; 55: 554-63.
13. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
14. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
15. Mecenate F, Pellicelli AM, Barbaro G, et al. Club Epatologi Ospedalieri (CLEO) Group. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the Cleo trial. BMC Gastroenterol 2010; 10: 21.
16. Dalgard O, Bjøro K, Ring-Larsen H, et al. North-C Group. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
17. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260-5.
18. Shiffman ML, Suter F, Bacon BR, et al. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
19. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
20. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
21. Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51: 1897-903.
22. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
23. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 2011; 31(Suppl. 1): 68-77.
24. McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
25. Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
26. Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-9. e1.
27. Pharmasset Inc. Pharmasset announces the expansion of the ELECTRON trial in chronic hepatitis C. Press release. June 8, 2011.
28. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 PegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naïve patients with G2/G3. J Hepatol 2011; 54: s28.
29. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009; 461: 399-401.
30. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
31. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
32. Asselah T, Bièche I, Sabbagh A, et al. Gene expression and hepatitis C virus infection. Gut 2009; 58: 846-58.
33. Sarasin-Filipowicz M, Krol J, Markiewicz I, et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15: 31-3.
34. Afdhal NH, McHutchison JG, Zeuzem S, et al. Pharmacogenetics and hepatitis C meeting participants. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 336-45.
35. Sarrazin C, Susser S, Doehring A, et al. Importance of Il28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
36. Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
37. Lindh M, Lagging M, Färkkilä M, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-52.
38. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; in press.
39. Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure. A genome wide association study. Gastroenterology 2010; 138: 1338-45.
40. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL 28B gene variant and sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
41. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-54.
42. von Wagner M, Huber M, Berg T, et al. Peginterferon alpha2a and ribavirin for 16 or 24 weeks in patients with genotype 2 and 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.